Evidence map›Paper›PMID 40593093›Full record

ArticleScientific reports2025

Continuous beta-2 microglobulin-based clearance highlights superiority of high-Dose HDF over high-flux HD in predicting outcomes.

Bernard Canaud, Andrew Davenport, Marion Morena-Carrere, Mailis Amico, Nicolas Molinari, Jean-Paul Cristol

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bernard CanaudNephrology-Dialysis, Intensive Care Unit -University of Montpellier, 9 Rue Des Carmelites, 34090, Montpellier, France. canaudbernard@gmail.com.
Andrew DavenportDepartment of Renal Medicine, UCL, Royal Free Hospital, University College London, London, UK.
Marion Morena-CarrereDepartment of Biochemistry and Hormonology, PhyMedExp, University of Montpellier, INSERM, CNRS, University Hospital Center of Montpellier, Montpellier, France.
Mailis AmicoClinical Research and Epidemiology Unit, University Hospital Center of Montpellier, University of Montpellier, Montpellier, France.
Nicolas MolinariClinical Research and Epidemiology Unit, University Hospital Center of Montpellier, University of Montpellier, Montpellier, France.
Jean-Paul CristolDepartment of Biochemistry and Hormonology, PhyMedExp, University of Montpellier, INSERM, CNRS, University Hospital Center of Montpellier, Montpellier, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies suggest that high-dose hemodiafiltration (HDF) may reduce mortality more effectively than high-flux hemodialysis (HD), though the mechanisms remain unclear. Traditional metrics such as Kt/V and convective volume do not fully capture overall dialysis efficiency. This study proposes a novel approach using circulating beta-2-microglobulin (ß2M) levels to estimate an equivalent Continuous Dialytic Clearance (eCDC

Indexed as

beta 2-MicroglobulinHemodiafiltrationKidney Failure, ChronicRenal DialysisAgedCardiovascular DiseasesFemaleGlomerular Filtration RateHumansMaleMiddle AgedTreatment Outcomebeta 2-MicroglobulinBeta-2-MicroglobulinEnd Stage Kidney DiseaseKidney Replacement TherapyMortalityPatient outcome

Identifiers

PMID40593093
PMCPMC12216211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.